Chemokine Binding Protein vCCI Attenuates Vaccinia Virus Without Affecting the Cellular Response Elicited by Immunization with a Recombinant Vaccinia Vector Carrying the HPV16 E7 Gene
Restricted accessResearch articleFirst published online October, 2012
Chemokine Binding Protein vCCI Attenuates Vaccinia Virus Without Affecting the Cellular Response Elicited by Immunization with a Recombinant Vaccinia Vector Carrying the HPV16 E7 Gene
Viral CC chemokine inhibitor (vCCI) of the clone P13 vaccinia virus (VACV) strain PRAHA lacks eight amino acids in the signal peptide sequence. To study the influence of vCCI on virus biology, a virus with the vCCI gene coding for a prolonged signal sequence was prepared. We found that secreted vCCI attenuated the virus in vivo, and that it correlated with decreased levels of RANTES, eotaxin, TARC, and MDC in the blood in comparison with the parental virus. We determined the influence of vCCI on the CTL response against VACV E3(140–148) (VGPSNSPTF) and HPV16 E7(49–57) (RAHYNIVTF) H-2Db-restricted epitopes. The examination of the specific CTL response elicited by immunization with the recombinant VACV-expressing tumor-associated HPV16 E7 antigen by IFN-γ ELISPOT showed that the immunogenicity of the recombinant VACV-producing secretory vCCI was similar to that of the parent virus or deletion mutant in the C23L/B29R locus. Immunization with the secretory vCCI-producing recombinant virus has a lower therapeutic anti-tumor effect against TC-1 tumors. Viral CCI downregulated the E7-specific response induced by gene gun immunization with the DNA vaccines pBSC-SigE7 LAMP and pBSC-vCCI. We also observed that the immune response against vCCI elicited by the DNA vaccine did not affect the multiplication of VACV in vivo.
Get full access to this article
View all access options for this article.
References
1.
RossiD, ZlotnikA. The biology of chemokines and their receptors. Annu Rev Immunol, 2000; 18:217–242.
2.
LeY, ZhouY, IribarrenP, WangJ. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol, 2004; 1:95–104.
3.
GlassWG, RosenbergHF, MurphyPM. Chemokine regulation of inflammation during acute viral infection. Curr Opin Allergy Clin Immunol, 2003; 3:467–473.
4.
AlcamiA, LiraSA. Modulation of chemokine activity by viruses. Curr Opin Immunol, 2010; 22:482–487.
5.
PatelAH, GaffneyDF, Subak-SharpeJH, StowND. DNA sequence of the gene encoding a major secreted protein of vaccinia virus, strain Lister. J Gen Virol, 1990; 71:2013–2021.
6.
AlcamiA, SymonsJA, CollinsPD, WilliamsTJ, SmithGL. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol, 1998; 160:624–633.
7.
GrahamKA, LalaniAS, MacenJLet al.The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology, 1997; 229:12–24.
8.
SmithCA, SmithTD, SmolakPJet al.Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology, 1997; 236:316–327.
9.
BurnsJM, DairaghiDJ, DeitzM, TsangM, SchallTJ. Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J Biol Chem, 2002; 277:2785–2789.
10.
ReadingPC, SymonsJA, SmithGL. A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol, 2003; 170:1435–1442.
11.
GoedeV, BrogelliL, ZicheM, AugustinHG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer, 1999; 82:765–770.
UenoT, ToiM, SajiHet al.Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res, 2000; 6:3282–3289.
14.
LissC, FeketeMJ, HasinaR, LamCD, LingenMW. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer, 2001; 93:781–785.
15.
SalcedoR, YoungHA, PonceMLet al.Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol, 2001; 166:7571–7578.
16.
HwangJ, KimCW, SonKNet al.Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett, 2004; 570:47–51.
17.
HwangJ, SonKN, KimCWet al.Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis. Cytokine, 2005; 30:254–263.
18.
StraslyM, DoronzoG, CappelloPet al.CCL16 activates an angiogenic program in vascular endothelial cells. Blood, 2004; 103:40–49.
19.
AdlerEP, LemkenCA, KatchenNS, KurtRA. A dual role for tumor-derived chemokine RANTES (CCL5)Immunol Lett, 2003; 90:187–194.
20.
SonKN, HwangJ, KwonBS, KimJ. Human CC chemokine CCL23 enhances expression of matrix metalloproteinase-2 and invasion of vascular endothelial cells. Biochem Biophys Res Commun, 2006; 340:498–504.
21.
MeliefCJ. Cancer immunotherapy by dendritic cells. Immunity, 2008; 29:372–383.
22.
Ben-BaruchA. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res, 2003; 5:31–36.
23.
KobayashiA, WeinbergV, DarraghT, Smith-McCuneK. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol, 2008; 1:412–420.
24.
LepiqueAP, DaghastanliKR, CuccoviaIM, VillaLL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res, 2009; 15:4391–4400.
25.
HarringtonKJ, PandhaHS, VileRG. Poxviruses as immunomodulatory cancer therapeutics. Viral Therapy of Cancer. John Wiley and Sons, Ltd.: Hoboken, NJ, 2007; 95–114.
26.
HsiehCJ, KimTW, HungCFet al.Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine, 2004; 22:3993–4001.
27.
MackovaJ, StasikovaJ, KutinovaLet al.Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother, 2006; 55:39–46.
28.
Corona GutierrezCM, TinocoA, NavarroTet al.Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther, 2004; 15:421–431.
29.
DavidsonEJ, FaulknerRL, SehrPet al.Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)Vaccine, 2004; 22:2722–2729.
30.
FianderAN, TristramAJ, DavidsonEJet al.Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer, 2006; 16:1075–1081.
31.
BoyleDB, CouparBE. A dominant selectable marker for the construction of recombinant poxviruses. Gene, 1988; 65:123–128.
32.
SmahelM, SimaP, LudvikovaV, VonkaV. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology, 2001; 281:231–238.
33.
KutinovaL, LudvikovaV, SimonovaVet al.Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine, 1995; 13:487–493.
34.
JoklikWK. The purification of four strains of poxvirus. Virology, 1962; 18:9–18.
35.
NemeckovaS, StranskaR, SubrtovaJet al.Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface. Cancer Immunol Immunother, 2002; 51:111–119.
36.
KutinovaL, LudvikovaV, MaresovaLet al.Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence. J Gen Virol, 1999; 80:2901–2908.
37.
MichlJ. Metabolism of cells in tissue culture in vitro. I. The influence of serum protein fractions on the growth of normal and neoplastic cells. Exp Cell Res, 1961; 23:324–330.
38.
ZurkovaK, BabiarovaK, HainzPet al.The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol Rep, 2009; 21:1335–1343.
39.
BabiarovaK, KutinovaL, KrystofovaJet al.Immunization with WT1 derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in miceSubmitted 2012.
40.
SmahelM, TejklovaP, SmahelovaJ, PolakovaI, MackovaJ. Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape. Cancer Immunol Immunother, 2008; 57:823–831.
41.
FeltkampMC, SmitsHL, VierboomMPet al.Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol, 1993; 23:2242–2249.
42.
LehmannMH, KastenmullerW, KandemirJD, BrandtF, SuezerY, SutterG. Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol, 2009; 83:2540–2552.
43.
TscharkeDC, ReadingPC, SmithGL. Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol, 2002; 83:1977–1986.
44.
AndrewME, CouparBE, BoyleDB. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immunol Cell Biol, 1989; 67:331–337.
45.
HembruffSL, ChengN. Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther, 2009; 7:254–267.
46.
SalcedoR, PonceML, YoungHAet al.Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood, 2000; 96:34–40.
47.
LobergRD, YingC, CraigMet al.Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res, 2007; 67:9417–9424.
CambienB, Richard-FiardoP, KarimdjeeBFet al.CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS One, 2011; 6:e28842.
50.
FridlenderZG, BuchlisG, KapoorVet al.CCL2 blockade augments cancer immunotherapy. Cancer Res, 2010; 70:109–118.
51.
DelaloyeJ, RogerT, Steiner-TardivelQGet al.Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog, 2009; 5:e1000480.
52.
SmahelM, SmahelovaJ, TejklovaP, TachezyR, MarinovI. Characterization of cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein. Int J Oncol, 2005; 27:731–742.
53.
KutinovaL, LudvikovaV, SimonovaVet al.Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine, 1995; 13:487–493.
54.
AppayV, Rowland-JonesSL. RANTES: a versatile and controversial chemokine. Trends Immunol, 2001; 22:83–87.
55.
RahbarR, MurookaTT, HinekAAet al.Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. J Virol, 2006; 80:7245–7259.
56.
RahbarR, MurookaTT, FishEN. Role for CCR5 in dissemination of vaccinia virus in vivo. J Virol, 2009; 83:2226–2236.
57.
HickmanHD, TakedaK, SkonCNet al.Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nat Immunol, 2008; 9:155–165.
SumidaSM, McKayPF, TruittDMet al.Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest, 2004; 114:1334–1342.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
